News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
181 Results
Type
Article (35)
Press Release (146)
Section
Business (44)
Deals (8)
Drug Development (54)
FDA (5)
Job Trends (2)
News (90)
Policy (10)
Tag
Academia (1)
Alliances (6)
Approvals (5)
Bankruptcy (1)
Best Places to Work (1)
Clinical research (54)
COVID-19 (6)
Data (5)
Diagnostics (1)
Earnings (29)
Events (37)
Executive appointments (1)
FDA (5)
Government (2)
Healthcare (1)
Immunology and inflammation (1)
Infectious disease (6)
IPO (7)
Layoffs (2)
Medical device (1)
Medtech (1)
Mergers & acquisitions (1)
NextGen: Class of 2026 (1)
People (12)
Phase 1 (11)
Phase 2 (38)
Phase 3 (21)
Pipeline (4)
Preclinical (3)
Rare diseases (2)
Real estate (3)
Regulatory (11)
Research institute (2)
Startups (1)
Date
Last 7 days (1)
Last 30 days (3)
Last 365 days (25)
2026 (3)
2025 (25)
2024 (24)
2023 (18)
2022 (31)
2021 (30)
2020 (16)
2019 (13)
2018 (12)
2017 (4)
2016 (2)
2014 (1)
Location
Asia (8)
Australia (1)
Europe (158)
Georgia (1)
Maryland (1)
Michigan (1)
North Carolina (1)
United States (4)
181 Results for "inflarx".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
InflaRx Stanches Spending With 30% Staff Reduction, Priority Pivot
Aside from the layoffs, InflaRx will deprioritize Gohibic, a COVID-19 antibody that was granted emergency use authorization in 2023. The therapy failed a late-stage trial in a rare skin disease last year.
January 9, 2026
·
1 min read
·
Tristan Manalac
Press Releases
InflaRx Announces Participation in February 2026 Investor Conferences
January 29, 2026
·
3 min read
Rare diseases
InflaRx Axes Rare Skin Disease Study on Disappointing Late-Stage Data
InflaRx’s vilobelimab met the bar for futility in a Phase III trial for the rare skin disease pyoderma gangrenosum.
May 28, 2025
·
2 min read
·
Tristan Manalac
Press Releases
InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum
December 30, 2025
·
12 min read
Press Releases
InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904
December 11, 2025
·
9 min read
Press Releases
InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference
October 21, 2025
·
2 min read
Press Releases
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
September 15, 2025
·
3 min read
Press Releases
InflaRx Announces Participation in September 2025 Investor Conferences
August 22, 2025
·
3 min read
Press Releases
InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria
November 10, 2025
·
3 min read
Press Releases
InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU)
November 10, 2025
·
20 min read
1 of 19
Next
